Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 161

Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (tocilizumab) for ...

This proposal is designed to help support a novel international clinical trial for children with the highly morbid brain tumor, Adamantinomatous Craniopharyngioma (ACP).  ACP is a solid/cystic tumor that originates in the sellar/suprasellar region at the base of the brain, adjacent to critical structures for vision, hormone ...

Modulation of intra-tumor hypoxia to sensitize DIPG irradiation and initiate ...

Malignant gliomas in specific region like brain pons are not curable as they cannot be surgically resected and are only transiently benefiting from local irradiation and in some cases from targeted therapies. These aggressive brain tumors are molecularly well known as they are characterized by a driver mutation. This abnormality ...

Targeting mitochondria-lysosome crosstalk as a therapeutic strategy for glioblastoma multiforme

Glioblastoma is the most common brain tumor. It is aggressive, and the therapeutic strategies focused on surgery, radiotherapy and chemotherapy are unable to destroy the tumor, which typically reappears post-treatment. The regrowth happens because the treatments are not able to destroy the cells that originate the tumor, called glioblastoma stem ...

Phase 2 Study of the MEK inhibitor MEKTOVI® (binimetinib) for the ...

This proposal is designed to help support a novel international clinical trial for children with the highly morbid brain tumor, Adamantinomatous Craniopharyngioma (ACP).  ACP is a solid/cystic tumor that originates in the sellar/suprasellar region at the base of the brain, adjacent to critical structures for vision, hormone ...

Precision Therapy to Overcome Chemoresistance in Pediatric Glioblastoma

Glioblastoma (GBM) remains one of the most aggressive and lethal forms of cancer. Despite the best available treatment options including surgical resection, radiotherapy, and chemotherapy, prognosis is poor in glioblastoma, with a median overall survival of 14 months.1Currently, temozolomide (TMZ) is the preferred chemotherapeutic drug in the treatment of GBM ...